Plus Therapeutics’ (PSTV) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a report issued on Thursday,Benzinga reports. D. Boral Capital currently has a $3.00 target price on the stock.

Several other equities analysts also recently weighed in on PSTV. HC Wainwright reissued a “buy” rating and issued a $1.00 price target (down from $2.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. Lake Street Capital began coverage on shares of Plus Therapeutics in a research report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Finally, Ascendiant Capital Markets reduced their price objective on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, November 21st. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $5.60.

Plus Therapeutics Trading Up 2.8%

Shares of Plus Therapeutics stock opened at $0.25 on Thursday. The firm has a market capitalization of $42.53 million, a PE ratio of -0.20 and a beta of 0.79. The firm’s 50-day moving average price is $0.28 and its 200 day moving average price is $0.47. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $1.77.

Institutional Trading of Plus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of PSTV. Jane Street Group LLC purchased a new stake in Plus Therapeutics during the second quarter worth approximately $41,000. Altium Capital Management LLC purchased a new stake in Plus Therapeutics in the third quarter valued at approximately $628,000. Scientech Research LLC acquired a new stake in Plus Therapeutics during the 3rd quarter worth $100,000. Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics during the third quarter worth about $46,000. Finally, Geode Capital Management LLC lifted its position in Plus Therapeutics by 72.5% during the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after acquiring an additional 589,544 shares during the period. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.